Zhi-Yuan Shi

Dr. Zhi-Yuan Shi

Taichung Veteran General Hospital
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CWChang Yi Wang
Chang Yi Wang
KHKao-Pin Hwang
Kao-Pin Hwang
HKHui-Kai Kuo
Hui-Kai Kuo
WPWen-Jiun Peng
Wen-Jiun Peng
YSYea-Huei Shen
Yea-Huei Shen
TMThomas Monath
Thomas Monath
Background. The Delta and Omicron variants of SARS-CoV-2 are currently responsible for breakthrough infections due to waning immunity. We report phase I/II trial results of UB-612, a multitope subunit vaccine containing S1-RBD-sFc protein and rationally designed promiscuous peptides representing sarbecovirus conserved helper T cell and cytotoxic T lymphocyte epitopes on the nucleocapsid (N), membrane (M), and spike (S2) proteins. Method. We conducted a phase I primary 2-dose (28 days apart) trial of 10, 30, or 100 μg UB-612 in 60 healthy young adults 20 to 55 years old, and 50 of them were boosted with 100 μg of UB-612 approximately 7 to 9 months after the second dose. A separate placebo-controlled and randomized phase II study was conducted with 2 doses of 100 μg of UB-612 (n = 3,875, 18–85 years old). We evaluated interim safety and immunogenicity of phase I until 14 days after the third (booster) dose and of phase II until 28 days after the second dose. Results. No vaccine-related serious adverse events were recorded. The most common solicited adverse events were injection site pain and fatigue, mostly mild and transient. In both trials, UB-612 elicited respective neutralizing antibody titers similar to a panel of human convalescent sera. The most striking findings were long-lasting virus-neutralizing antibodies and broad T cell immunity against SARS-CoV-2 variants of concern (VoCs), including Delta and Omicron, and a strong booster-recalled memory immunity with high cross-reactive neutralizing titers against the Delta and Omicron VoCs. Conclusion. UB-612 has presented a favorable safety profile, potent booster effect against VoCs, and long-lasting B and broad T cell immunity that warrants further development for both primary immunization and heterologous boosting of other COVID-19 vaccines. Trial Registration. ClinicalTrials.gov: NCT04545749, NCT04773067, and NCT04967742. Funding. UBI Asia, Vaxxinity Inc., and Taiwan Centers for Disease Control, Ministry of Health and Welfare.

1 June 2020 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Open access
WHWei-Hsuan Huang
Wei-Hsuan Huang
LTLing-Chiao Teng
Ling-Chiao Teng
TYTing-Kuang Yeh
Ting-Kuang Yeh
YCYu-Jen Chen
Yu-Jen Chen
WLWei-Jung Lo
Wei-Jung Lo
PLPo-Yu Liu
Po-Yu Liu
We reported two cases with community-acquired pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who returned from Wuhan, China in January, 2020. The reported cases highlight non-specific clinical presentations of 2019 novel coronavirus disease (COVID-19) as well as the importance of rapid laboratory-based diagnosis.

1 June 2015 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Closed access
STShu-Ting Tseng
Shu-Ting Tseng
CTChun-Hsi Tai
Chun-Hsi Tai
CLChia-Ru Li
Chia-Ru Li
CLChin-Fu Lin
Chin-Fu Lin
Zhi-Yuan ShiZhi-Yuan Shi
Zhi-Yuan Shi

1 June 2014 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Closed access
SHSz-Rung Huang
Sz-Rung Huang
MLMeei-Fang Liu
Meei-Fang Liu
CLChin-Fu Lin
Chin-Fu Lin
Zhi-Yuan ShiZhi-Yuan Shi
Zhi-Yuan Shi

1 April 2008
Verified
Journal Article
Closed access
PHPo-Pin Hung
Po-Pin Hung
YLYu-Hui Lin
Yu-Hui Lin
CLChin-Fu Lin
Chin-Fu Lin
MLMeei-Fang Liu
Meei-Fang Liu
Zhi-Yuan ShiZhi-Yuan Shi
Zhi-Yuan Shi

1 December 2021 in American Journal of Infection Control
Verified
Journal Article
Open access
YCYing-Chun Chen
Ying-Chun Chen
HHHui-Mei Huang
Hui-Mei Huang
PLPei-Yi Lin
Pei-Yi Lin
Zhi-Yuan ShiZhi-Yuan Shi
Zhi-Yuan Shi
Environmental cleaning is an effective measure to prevent infections. However, performance observation has been rarely delineated. This study aimed to compare correlations among visual inspection, performance observation, and effectiveness by using adenosine triphosphate bioluminescence (ATP bioluminescence) as a comparator to find out which method is better to assess hospital cleanliness. This prospective study was conducted at a medical center from April 2019 to October 2020. Seven high-touch surfaces were evaluated during and after terminal cleaning by performance observation, visual inspection, and ATP bioluminescence. The scores by performance observation, visual inspection, and ATP were 55.4%, 87.5%, and 26.6% after cleaning. The correlations between performance observation and visual inspection and between performance observation and ATP interpretation were weak positive (φ = 0.300, 0.324, P < .001). No correlation was between the visual inspection and ATP interpretation (φ=0.137). The median of ATP readings was lower in "compliant" group by performance observation and "clean" group by visual inspection than "not compliant" group and "not clean" group (P < .001). Performance observation combined with ATP would be preferred to include to audit cleanliness on high-risk surfaces. Visual inspection would be a rapid and time-saving assessment tool on low-risk surfaces.